Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.55 USD | -0.58% | -7.26% | -26.79% |
May. 23 | Some of the biggest splits in Corporate America | RE |
May. 21 | The latest transactions by star managers |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.79% | 2.28B | - | ||
+67.53% | 63.85B | B- | ||
-0.77% | 41.83B | B | ||
+45.66% | 40.65B | A | ||
-10.72% | 27.12B | C | ||
+13.30% | 26.52B | B- | ||
-22.79% | 18.69B | B | ||
+4.70% | 12.73B | B+ | ||
+24.10% | 12.11B | B+ | ||
+27.41% | 12.07B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- FTRE Stock
- Ratings Fortrea Holdings Inc.